India's Covid-19 case tally rose by 134 in a day while the number of active cases has declined to 1,962 according to the Union Health Ministry data updated on Thursday.
India has so far recorded 4.46 crore Covid cases. The death toll stood at 5,30,728, the data updated at 8 am stated.
The daily positivity was recorded at 0.07 per cent while the weekly positivity was 0.08 per cent. Active cases now comprise 0.01 per cent of the total infections, while the national Covid-19 recovery rate has increased to 98.80 per cent, according to the health ministry website.
Active caseload declined by 36 cases in 24 hours. The number of people who have recuperated from the disease surged to 4,41,48,815, while the case fatality rate was recorded at 1.19 per cent.
According to the ministry's website, 220.20 crore doses of Covid vaccine have been administered in the country so far under the nationwide Covid-19 vaccination drive. India's Covid-19 tally crossed the 20-lakh mark on August 7, 2020, 30 lakh on August 23, 40 lakh on September 5 and 50 lakh on September 16. It went past 60 lakh on September 28, 70 lakh on October 11, crossed 80 lakh on October 29, 90 lakh on November 20 and surpassed the one-crore mark on December 19. India crossed the grim milestone of three crore on June 23 last year and four crore on January 25 this year.
On Wednesday, India logged 128 new coronavirus infections, while the active cases declined to 1,998, according to the Union Health Ministry data updated on Wednesday. The Covid case tally was recorded at 4.46 crore.
SII seeks inclusion of Covid jab Covovax in CoWIN portal
Meanwhile, the Serum Institute of India has written to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults. The letter was written by Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII).
National Technical Advisory Group on Immunisation (NTAGI) is likely to hold a meeting soon to decide on the matter.
The Drug Controller General of India (DCGI) on January 16 approved market authorisation for Covovax as a heterologous booster dose for adults who have been administered two doses of either Covishield or Covaxin.
Its approval was based on recommendations by the subject expert committee (SEC) of the Central Drugs Standard Control Organisation.
The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and also in children aged seven to 11 years on June 28 last year subject to certain conditions.
Covovax is manufactured through technology transfer from Novavax.